Transition from compensated hypertrophy to systolic heart failure in the spontaneously hypertensive rat: Structure, function, and transcript analysis  by Brooks, Wesley W. et al.
Genomics 95 (2010) 84–92
Contents lists available at ScienceDirect
Genomics
j ourna l homepage: www.e lsev ie r.com/ locate /ygenoTransition from compensated hypertrophy to systolic heart failure in the
spontaneously hypertensive rat: Structure, function, and transcript analysis
Wesley W. Brooks a,b,⁎, Steven S. Shen c, Chester H. Conrad a,b, Ronald H. Goldstein a,b, Oscar H.L. Bing a,b
a From the VA Boston Healthcare System, 150 South Huntington Avenue, Boston, MA 02130, USA
b Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
c Clinical and Translational Science Institute, Boston University School of Medicine, Boston, MA 02118, USA⁎ Corresponding author. VA Boston Health Care Syste
127), 150 South Huntington, Avenue, Boston, MA 02130
E-mail addresses: wesley.brooks@va.gov, brooksww
0888-7543/$ – see front matter. Published by Elsevier
doi:10.1016/j.ygeno.2009.12.002a b s t r a c ta r t i c l e i n f oArticle history:
Received 20 August 2009
Accepted 5 December 2009
Available online 16 December 2009
Keywords:
Heart failure
Hypertension
Cardiac hypertrophy
Gene expression microarrayGene expression, determined by micro-array analysis, and left ventricular (LV) remodeling associated with
the transition to systolic heart failure (HF) were examined in the spontaneously hypertensive rat (SHR). By
combining transcript and gene set enrichment analysis (GSEA) of the LV with assessment of function and
structure in age-matched SHR with and without HF, we aimed to better understand the molecular events
underlying the onset of hypertensive HF. Failing hearts demonstrated depressed LV ejection fraction, systolic
blood pressure, and LV papillary muscle force while LV end-diastolic and systolic volume and ventricular
mass increased. 1431 transcripts were differentially expressed between failing and non-failing animals. GSEA
identiﬁed multiple enriched gene sets, including those involving inﬂammation, oxidative stress, cell
degradation and cell death, as well as TGF-β and insulin signaling pathways. Our ﬁndings support the
concept that these pathways and mechanisms may contribute to deterioration of cardiac function and
remodeling associated with hypertensive HF.
Published by Elsevier Inc.Background
The spontaneously hypertensive rat (SHR) is a useful laboratory
model of genetic hypertension and naturally evolving hypertensive
heart disease [1] that has enabled investigators to study changes in
structure and function during the transition to heart failure (HF) [2-4].
More recent studies have shown alterations in cardiac gene
expression in association with phenotypic changes related to
ventricular remodeling associated with HF. Clinical studies of gene
expression have been carried out in failing human hearts with
coronary artery disease [5] and dilated cardiomyopathy [6]. Experi-
mental studies have examined a number of models of HF , including
transgenic rats with overexpression of the human renin (Ren) and
angiotensinogen (Agt) genes [7], Dahl salt-sensitive rats [8,9], TNFα
(Tnf) overexpressing mice [10], transgenic mice with compensated
hypertrophy and HF [11], and dogs with chronic rapid ventricular
pacing [12,13]. Differences with respect to identiﬁed transcripts have
been described in different models of HF. When all transcript analysis
of HF are taken together, however, a common HF proﬁle emerges that
appears to indicate that genes encoding transcription factors,
remodeling/repair, the immune system, cell communication and
cell death, including apoptosis, and stress response genes, were up-m (151), Research Building (R-
, USA.
@bu.edu (W.W. Brooks).
Inc.regulated [6–13] whereas potassium current transcripts [14,15],
mitochondrial transcription factors, lipid and glucose metabolism
transcripts [7,12,16–19] were down-regulated in failing compared to
non-failing controls. Despite the many transcript changes found, the
mechanism(s) underlying transition from adaptive cardiac hypertro-
phy to HF remains poorly understood.
Despite the importance of the SHR model, to our knowledge, only
one study has been carried out using microarray gene chip analysis of
the aging SHR to study HF [20]. This study compared differences
between 12- and 16-month-old SHR with compensated LV hypertro-
phy and 20-month-old animals with diastolic dysfunction and HF;
these SHR exhibited changes in diastolic properties of the heart, while
systolic function was unimpaired. Changes were attributed to
upregulation of the extracellular matrix (ECM) while the broad
array of transcript changes found in other studies of HF [6–13,18,19]
were not found. The apparent divergence between these ﬁndings and
those in other models of HF may be related to differences between
diastolic and systolic HF, species differences, or possibly differences in
statistical analysis.
In an effort to improve the discovery of differentially expressed
transcripts in the SHR with systolic HF, as demonstrated by LV and
isolated papillary studies, individual LV samples from six SHR and six
age-matched SHR with compensated hypertrophy were studied by
micro-array gene expression analysis. In addition, Gene Set Enrich-
ment Analysis (GSEA) was carried out in order to elucidate pathways
involved [21].
Fig. 1. Serial echocardiographic measurements in SHR. LV ejection fraction (left panel)
and end-systolic and end-diastolic LV volume (right panel) of male SHR during the
transition to heart failure (12, 17, and 19 months of age). EF, indicates LV ejection
fraction (%); ESV, end-systolic volume (ml; black circle); EDV, end-diastolic volume
(ml; open circle). LV function remains compensated until approximately 17 months,
and then rapidly declines; mean age at onset of HF 19±1 months.
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Development of HF
Sixteen 12-month-old SHR were initially entered into the study;
four died prior to study. Of the surviving twelve SHR, six developed
evidence of HF (SHR-F), and were compared to six additional SHR
without HF (SHR-NF). Animals were considered to have HF when
based on documentation of left ventricular dysfunction echocardiog-
raphy ﬁndings, speciﬁcally LV enlargement with LV ejection fraction
b55% (normal N80%). Pathological ﬁndings associated with heart
failure included pleural and/or pericardial effusions, left atrial or LV
thrombi, and right ventricular hypertrophy, as described previously
[3,4,22–24]. Peak systolic blood pressurewas 145±8mmHg in SHR-F,
as compared to 185±5mmHg in SHR-NF. Themean age at the time of
study (19±1months)was not signiﬁcantly different between groups.
Echocardiography
Serial echocardiographic measurements of LV ejection fraction
(LVEF) and LV volumes were carried out beginning at 12 months of
age and approximately every 8 weeks thereafter until the develop-
ment of HF. LVEF in 12-month-old animals (without HF) is
approximately 90%, gradually declined with age to approximately
83 to 84% in non-failing SHR at 17 months of age, and to 54.2±4%
with HF. Echocardiographic ﬁndings of SHR hearts without HF (SHR-
NF) and SHR at the time of HF (SHR-F) are presented in Table 1. LV
ejection fraction and fractional shortening, used as measures of
systolic function, decreased signiﬁcantly, while LV end-diastolic and
end-systolic chamber dimensions increased with HF (Fig. 1).
Pathological parameters
Body weight, cardiac chamber weights, and chamber weights
normalized for body weight are presented in Table 2. Body weight
decreased, and the LV and, to a greater extent, RV weight increased in
SHR with HF relative to non-failing SHR (pb0.01). Body weight was
signiﬁcantly reduced (pb0.05), and LV/BW and RV/BW ratio signiﬁ-
cantly increased, in SHR-F relative to SHR-NF. Myocardial and liver
water content data is also presented in Table 2. Left ventricular and liver
water content (expressed as g water/g dry wt) was increased in SHR
with HF compared to SHR with compensated hypertrophy (pb0.05).
Isolated muscle data
Isometric papillary muscle data from SHR-NF and SHR-F are
summarized in Table 3; peak active isometric stress and quick-releaseTable 1
Echocardiographic measurements.
SHR-NF SHR-F
Initial Time of study Initial Time of study
LVEF% 89.2±6.0 83.7±5.2 90.9±4.4 54.2±4.5⁎
LVFS% 55.5±5.5 46.8±7.8 56.7±5.3 23.1±2.6⁎
LVEDDmm 7.32±0.66 7.54±0.78 7.23±0.89 9.75±0.72⁎
LVESDmm 3.40±0.39 4.00±0.66 3.25±0.41 7.45±0.69⁎
EDVtzml 0.89±0.22 0.98±0.27 0.88±0.32 1.93±0.40⁎
ESVtzml 0.14±0.06 0.17±0.07 0.10±0.05 0.93±0.24⁎
SHR-NF indicates spontaneously hypertensive ratswithout HF, initial echocardiographic
data obtained at 12 months of age, and at time of study; SHR-F, spontaneously
hypertensive rats with HF, initial echocardiographic data obtained at 12 months of age,
and at time of study. LVEF, left ventricular ejection fraction; LVFS, left ventricular
fractional shortening; LVEDD, left ventricular end-diastolic diameter; LVESD, left
ventricular end-systolic diameter; EDVtz, end-diastolic volume (Teichholz); ESVtz,
end-systolic volume (Teichholz).
Values are mean of six rats per group ±SD. ⁎pb0.05 SHR-F vs. SHR-NF at the time of
study.force–velocity relationships are presented in Fig. 2. Papillary muscle
cross-sectional area was not signiﬁcantly different between SHR
groups. In SHR-F, active isometric stress (σactive, active developed
tension normalized for muscle cross-sectional area) and maximum
rate of stress development (+dσ/dt) were depressed, and relaxation
time signiﬁcantly abbreviated, relative to SHR-NF. Myocardial
stiffness was signiﬁcantly increased in SHR-F compared to SHR-NF
(Table 3). Velocity of shortening was less at all loads examined in
papillary muscles from SHR-F than SHR-NF (pb0.01).
Response to β-adrenergic stimulation
Peak σ, +dσ/dt, and time to peak σ were determined at muscle bath
isoproterenol (ISO) concentrationsof10−8 and10−7mmol/l. In SHR-F, 10−7
ISO decreased peak σ by 16±2% of pre-ISO control, and +dσ/dt was
unchanged. In SHR-NF, peakσwas unchanged and+dσ/dt increased by 14
±4% at 10−7 ISO. Time to peak σ and relaxation time index decreased by
approximately 15% and 25%, respectively, with ISO in both groups (NS).
Histology
Fig. 3 is a cross-section of the LV from SHR-NF and SHR-F stained
with Masson's trichrome. Representative sections of LV-free wall and
LV papillary muscles from SHR-NF and SHR-F were assessed by
quantitative histological analysis. Table 4 presents quantitative
connective tissue and myocyte area data. Myocardial ﬁbrosis was
increased in LV and papillary muscle samples from SHR-F relative to
SHR-NF (pb0.05) and to a greater extent relative to age-matched
normotensive WKY (LV average 8.3±4.0%; WKY data not shown).
Differentially expressed LV transcripts between SHR-F and SHR-NF
A total of 1,431 transcripts were found to be differentially
expressed in LV samples from SHR-F relative to SHR-NF (pb0.05) by
microarray analysis. Of these, 484 transcripts (294 upregulated and
190 downregulated) were positively identiﬁed with known biological
function. Fig. 4 is an example of four highly expressed transcripts that
were down- and ﬁve up-regulated with HF, obtained from six
individual LV samples from SHR-F (left panel) and SHR-NF (right
panel). In general, the extent of expression changes appeared to be
related to the extent of myocardial impairment. The top 25 identiﬁed
transcripts that were most substantially up- and down-regulated are
presented in Tables 5 and 6, respectively. (See supplemental tables for
a complete list of all identiﬁed transcripts differentially expressed
with HF).
Table 2
Cardiac chamber weight, body weight, ratios and tissue water content.
LV (g) RV (g) BW (g) LV/BW (mg/g) RV/BW (mg/g) LV/TL (mg/cm) LV (wet/dry) Liver (wet/dry)
SHR-NF 1.36±0.12 0.24±0.03 404±27 3.36±0.34 0.59±0.09 0.32±0.02 3.68±0.09 2.22±0.27
SHR-F 1.43±0.14 0.40±0.06+ 366±24+ 3.90±0.33⁎ 1.11±0.17+ 0.36±0.03 3.85±0.14⁎ 2.58±0.15⁎
LV, left ventricular weight; RV, right ventricular weight; BW, body weight; LV/BW, left ventricular weight to body weight ratio; RV/BW, right ventricular weight to body weight
ratio; LV/TL, left ventricular weight to tibia length ratio; LV, left ventricular water content expressed as g water/g dry tissue wt; Liver, water content expressed as g water/g dry
tissue wt.
Data are mean of 6 rats per group ±SD. ⁎pb0.05 SHR-F vs. SHR-NF; +pb0.01 SHR-F vs. SHR-NF.
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regulatory enzymes (e.g. pyruvate dehydrogenase kinase (Pdk2),
glycerol-3-phosphate dehydrogenase 2 (Gpd2), phosphofructokinase
(Pfkm) and phosphoglycerate mutase 2 (Pgam2)). Several transcripts
involved in fatty acid oxidation were decreased with HF (e.g. enolyl-
coenzyme A, hydratase/3-hydroxyacyl coenzyme A dehydrogenase
(Ehhadh), acyl-coenzyme A dehydrogenase; and, solute carrier family
25, carnitine acetytransferase (S1c25a20) and carnitine palmitoyl-
transferase 2 (Cpt2), and L-3-hydroxyacyl-Coenzyme A dehydroge-
nase, short chain (Hadh)). In addition, cardiac and mitochondrial
speciﬁc 3-hydroxybutyrate dehydrogenase (Bdh1) and adenosine
triphosphate cassette transporter were signiﬁcantly downregulated in
the SHR-F group. The signal transduction gene RASD member 2
(Rasd2) was also markedly downregulated in the LV from SHR-F
relative to compensated SHR.
Themost highly down-regulated transcripts found in the SHR-F vs.
SHR-NF were related to cardiac contractile apparatus and included
myosin, heavy polypeptide 7 (Myh7), cardiac muscle, beta and
myosin heavy chain, polypeptide 6. On the other hand, the most
highly expressed transcript of the LV from the SHR-F group was the
immunomodulatory gene lipopolysaccharide binding protein (Lbp).
Nuclear protein 1 (Nupr1), a transcription factor associated with the
induction of apoptosis, was also highly expressed in the SHR-F group.
Expression of the extracellular matrix (ECM) related transcripts
ﬁbronectin (Fn1), lysyl oxidase (Lox), and cathepsin S (Ctss) was
signiﬁcantly elevated in the SHR-F vs. SHR-NF. Several transcripts often
associated with human HF (e.g. arginine-vasopressin (Avp), dopamine
hydroxylase (Dbh), and transcripts involved in tumor necrosis factor-α
(Tnf) and transforming growth factor beta-1 (Tgfb1) signaling path-
ways) were also found to be up-regulated in the SHR-F group.
Gene function and pathway enrichment with systolic HF
The functional outcomes of the GSEA and GO-based analysis are
summarized in Table 7. In gene sets C2 collection (SHR with HF vs. age-
matched, SHR without HF), a total of 1,340 gene sets were tested. In this
analysis, 993 gene sets were upregulated and 347 genes sets were
downregulated with systolic HF. A total of 83 pathways and curated
signature related gene sets were signiﬁcantly enriched in terms of
nominal p-value less than 0.01 (See supplemental tables for pathway
details). Pathways involving TGF-β and insulin signaling were highly
enriched. Additional gene sets thatwere alteredwithHF includeoxidative
stress, complement and coagulation pathways, cell and structure
degradation, apoptosis, metabolism, cell adhesion, and inﬂammation.Table 3
Isolated papillary muscle parameters.
CSA
(mm2)
+dσ/dt
(g/mm2/s)
TPS
(ms)
RT1/2
(ms)
Kcs
(stiffness)
SHR-NF 1.4±0.37 43.1±8.6 176±20 188±14 53±4
SHR-F 1.42±0.39 22.2±6.8⁎ 184±13 144±14⁎ 74±15⁎
CSA, indicates cross-sectional area of LV papillary muscle; +dσ/dt, rate of stress
development; TPS, time to peak stress; RT1/2, relaxation time index; Kcs, myocardial
stiffness constant. Data are mean of six papillary muscles per group±SD. ⁎pb0.05 SHR-
F vs. SHR-NF.Gene sets C5 collection, a total 926 gene sets were tested (564 gene
sets upregulated and 362 gene sets downregulated with HF). A total of
34GO term function related gene setswere signiﬁcantly enriched at the
level of nominal p-value less than 0.01 (Table 8). Overexpressed GO
classes of the LV from failing SHR most prominent of which were
biological processes involved in cell signaling pathways, binding of
cellular constituents and cell death. The enriched gene sets whichmeet
criteria of nominal p-value less than 0.05 are provided as supplements.
Conﬁrmation of expression changes
To validate changes in transcripts from microarray data, quanti-
tative PCR was performed on a subset of transcripts from SHR-NF and
SHR-F (Table 9). Ten transcripts were selected for quantitative
analysis; seven were up-regulated with HF by gene chip analysis
(i.e. lipopolysaccharide binding protein (Lbp), cathepsin S (Ctss), lysyl
oxidase (Lox), dopamine beta-hydroxylase (Dbh), arginine vasopres-
sin (Avp), cAMP response element modulator (Crem), and
programmed cell death 4 (Pdcd4)), and three genes were down-
regulated (i.e. RASD family member 2 (Rasd2); L-3-hydroxyacyl-
Coenzyme A dehydrogenase, short chain (Hadh); and acyl-CoenzymeFig. 2. (A) Active tension (AT) of LV papillary muscles. AT was signiﬁcantly depressed
(pb0.01) in SHR-F in comparison to SHR-NF. (B) Quick release force–velocity (F–V)
relationships from LV papillary muscles. F-V relationships were signiﬁcantly depressed
(pb0.01) in SHR-F in comparison to SHR-NF. Data are mean±SD (n=6 per group).
Fig. 3. High power (25×) cross-section stained with Masson's trichrome from non-failing SHR (left panel) and SHR with HF (right panel). The sections were obtained half way
between LV apex and base. There is marked ﬁbrosis of the LV from SHR-F.
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with HF, as determined by microarray analysis, were qualitatively
consistent with the results obtained by real-time PCR, and corroborate
our microarray ﬁndings. The immunomodulatory transcript Lbp was
the most highly correlated transcript determined by RT-PCR and
microarray analysis (r=0.94; pb0.0001).
Functional correlates
The level of Lbp expression, which was markedly up-regulated in
the LV by microarray and RT-PCR with HF, was negatively correlated
(r=−0.76; p=0.004) to maximum active tension developed by LV
papillary muscles from the same heart (Fig. 5A. Increased myocardial
stiffness associated with HF was directly correlated (r=0.70;
p=0.0169; Fig. 5B) to the expression level of lysyl oxidase (Lox)
from individual papillary muscles determined by microarray and RT-
PCR. Thus, the extent of myocardial dysfunction of LV papillary muscles
correlatedwith LV expression of the immunomodulatory transcript Lbp
and the collagen-cross linking enzyme lysyl oxidase (Lox).
Discussion
Cardiac phenotype
This study deﬁnes changes in the SHR heart during the transition
to systolic HF. Pathologic assessment of the heart reveals LV and RVTable 4
Histological analysis.
n LV papillary muscles LV free wall
Myocyte
(fractional area,%)
Connective tissue
(fractional area,%)
Connective tissue
(fractional area,%)
SHR-NF 6 69.8±6.8 16.2±2.0 12.1±1.6
SHR-F 6 64.9±3.7 21.9±2.8⁎ 19.1±1.6⁎
Histological ﬁndings (myocytes, connective tissue) expressed as a % of total area from
analysis of cross-sections of LV papillary muscles and LV free wall samples. These data
are from SHR in which physiological and gene expression studies were carried out.
Values are mean±SD.
⁎ pb0.05 SHR-F vs. SHR-NF.hypertrophy, ﬁbrosis and increased LV water content in the SHR-F
compared with age-matched SHR-NF, consistent with prior studies
[3,4,22–24]. Echocardiographic data demonstrate a reduction in LV
ejection fraction and an increase in LV diastolic and systolic
dimensions in the SHR-F (see Table 1). An analysis of isolated LVFig. 4. Individual expression levels of transcripts from the LV of SHR with and without
HF. Examples of several structural and functional transcripts that were signiﬁcantly
down-regulated with HF (top four) and cell defense (i.e. immune and inﬂammatory
transcripts) that were up-regulated with HF (bottom ﬁve). Myh7, indicates myosin,
heavy polypeptide 7, cardiac muscle, beta; Myh6, myosin heavy chain, polypeptide 6;
Kcnk2, potassium channel, subfamily K, member 2; Kcna2, potassium voltage-gated
channel, shaker-related subfamily, member 2; Lbp, lipopolysaccharide binding protein;
Il1r1, interleukin 1 receptor, type I; Fn1, ﬁbronectin 1; C4a, complement component 4a;
Fcgr2b, Fc receptor, IgG, low afﬁnity IIb. The blue colored samples represent lower
expression levels while red indicates higher expression. White indicates no changes in
mRNA-expression occurred. Statistical signiﬁcance comparing SHR-F to SHR-NF values
is presented in the last column.
Table 5
Top 25 transcripts that were signiﬁcantly up-regulated with HF (pb0.05). Up-regulated
transcripts ranked by fold change.
Identiﬁer Gene title p Fold change
FDR F/NF Function Chrom.
BF289368 Lipopolysaccharide
binding protein
0.0057 0.0115 6.11 CD 2
AB001382 Secreted
phosphoprotein 1
0.0139 0.0251 4.37 CS 5
NM_013123 Interleukin 1 receptor,
type I
0.0002 0.0091 3.95 CD 1
BG380575 Neuronal pentraxin
receptor
0.0001 0.0065 3.72 TT 15
AA893484 Fibronectin 1 0.0039 0.0135 3.65 S/CD 1
NM_031521 Neural cell adhesion
molecule 1
0.0017 0.0122 3.58 CA/TT 9
BI285347 Complement
component 4a
0.0025 0.0129 3.56 CD 17
AF187814 Camello-like 3 0.0005 0.0092 3.4 TT 6
U23438 Dual speciﬁcity
phosphatase 4
0.0004 0.0092 3.37 CS 8
AI179988 Ectodermal-neural
cortex 1
0.0077 0.0181 3.24 CA/PM 13
AA850692 Activin receptor
interacting protein 1
0.0009 0.0114 3.24 CS 5
AI230669 Guanine nucleotide
binding protein, beta 1
0.0335 0.0486 3.17 CS 4
NM_053433 Flavin containing
monooxygenase 3
0.0083 0.0185 3.14 EM 1
NM_053611 Nuclear protein 1 0.0015 0.0116 3.11 TT 7
X89963 Thrombospondin 4 0.0014 0.0118 3.09 CA 13
NM_053326 Enigma homolog 0.0010 0.0113 2.96 CS 3
NM_031832 Lectin, galactose
binding, soluble 3
0.0035 0.0136 2.9 CA/PM 14
AF202115 Ceruloplasmin 0.0118 0.0226 2.79 T 3
NM_012620 Serine (or cysteine)
proteinase inhibitor,
clade E, member 1
0.0181 0.0301 2.77 CS/TT 5
NM_012620 Serine (or cysteine)
proteinase inhibitor,
clade F, member 1
0.0062 0.0161 2.77 CS/TT 11
X73371 Fc receptor, IgG, low
afﬁnity IIb
0.0034 0.0135 2.75 CD 1
AA850991 Chondroitin sulfate
proteoglycan 2
0.0008 0.0111 2.75 CA 13
AI407489 Solute carrier organic
anion transporter
family, member 2a1
0.0016 0.0121 2.75 T 9
BF419200 CCAAT/enhancer
binding protein
(C/EBP), delta
0.0005 0.0091 2.73 TT 16
NM_021586 Latent transforming
growth factor beta
binding protein 2
0.0082 0.0184 2.73 CS 12
B, Biosynthesis/general metabolism; CA, cell adhesion or binding activity; CD, cell defense
(i.e. immunity/oxidative stress); CS, cell signaling/communication; D, death associated;
G, cell growth/maintenance; EM, energy metabolism; PM, protein or structural modiﬁer;
S, cell structure (i.e. ECM) or function (i.e. contraction); T, transport; TT, transcription/
translation regulatory activity; O, other unclassiﬁed function. Chrom indicates
chromosome location. The same format applies for Tables 5 and 6.
88 W.W. Brooks et al. / Genomics 95 (2010) 84–92papillary muscle function demonstrates depressed active tension and
shortening velocity, and increased myocardial stiffness, in SHR-F
compared with SHR-NF (Table 3). These ﬁndings support the concept
that depressed cardiac function, demonstrated by echocardiography,
is due to impaired intrinsic contractile properties of the myocardium.
Changes in LV gene expression
Previous transcriptomic studies of various HF models have noted
differences in the number and proﬁle of identiﬁed transcripts. For
example, HF in the TNFα overexpressing mouse model is charac-
terized by an increase in expression of inﬂammatory cytokines [10]
Dahl salt-sensitive rats exhibit an increase in apoptosis transcripts[8,9]. Microarray gene expression proﬁles of HF due to dilated
hypertrophic cardiomyopathy have been associated with down-
regulation of SR/endoplasmic reticulum and Ca2+-ATPase tran-
scripts, and the upregulation of ECM transcripts [5]. Studies of pacing
inducedHF found that energy andmetabolism-related transcriptswere
down-regulated with HF [12], and oxidative stress transcripts were
upregulated [13]. Taken together, however, studies in general indicate
that genes encoding transcription factors, remodeling/repair, the
immune system, cell communication and cell death, including
apoptosis, and stress response genes, were up-regulated [6–9,12,13]
whereas potassium current transcripts [14,15], mitochondrial tran-
scription factors, lipid and glucose metabolism transcripts [7,12,16–
19] were down-regulated in failing compared to non-failing controls.
(For a systemic review of large scale and heterogenous gene array data
in HF see [25]).
A previous study employing DNA microarray analysis of the aging
SHR found that relatively few transcripts were altered during the
development of diastolic dysfunction [20]. In their study, differences
between 12- and 16-month-old SHR with compensated LV hypertro-
phy were compared to 20-month-old animals with diastolic dysfunc-
tion; ﬁndings included increases in extracellular matrix (ECM)
transcripts, while differences in calcium homeostasis, contractile,
cytoskeletal, neurohumoral and energy transcripts were not found.
These apparent divergence between these ﬁndings and those in other
models of HF may be related to differences between diastolic and
systolic HF, species differences, or possibly differences in statistical
analysis, in that small sample sizes may limit sensitivity for
identiﬁcation of changes.
In the present study, initial microarray analysis indicated a total of
1,431 transcripts were differentially expressedwith HF of which, 484
(294 up regulated and 190 down-regulated) transcripts were
positively identiﬁed. The immunomodulatory gene lipopolysaccha-
ride binding protein (Lbp) was the single most highly expressed
transcript (i.e. greater than 6 fold increase) in failing relative to non-
failing LV, and was negatively correlated to force generation
when compared with papillary muscle function from the same LV
(R −0.76; Fig. 5A). When compared to age-matched, normotensive
WKY rats, Lbp expression in LV from the SHR-F group was more than
26-fold greater (unpublished observation). Lbp also has been found
to be the most highly expressed transcript with systolic dysfunction
induced by coronary artery occlusion [26]. Together, these ﬁndings
suggest that up-regulation of expression of mediators of inﬂamma-
tion are a common features in these two models of systolic
dysfunction, and that Lbp expression might potentially serve as a
biomarker of myocardial dysfunction.
An upregulated immune and inﬂammatory response is well
recognized to be a feature of the pathophysiology of chronic HF
resulting frommany causes [27]. Elevated expression of inﬂammatory
cytokines TNF-α and TGF-β1 have been demonstrated in patients with
severe HF [27,28], and in the SHR [24,29,30]. Inﬂammation and the
inﬂammatory cytokine TGF-β1, in particular, has been shown to alter
lipid metabolism and decrease fatty acid oxidation in the kidney [31]
and heart [32] which may account, in part, for the downregulation of
transcripts involved in energy metabolism and fatty acid oxidation
found in the SHR with HF.
A 2.5-fold elevation of cathepsin S (Ctss) transcripts was found in
the SHR-F group. Cathepsin S, a cysteine protease, plays a role in the
degradation of peptide chains; in particular those associated with the
immune response [33], and has been shown to participate in
pathological remodeling of the LV associated with hypertension-
induced HF in humans and rats [34]. Thus, cathepsin S may contribute
to adverse LV remodeling found in the SHR-F.
The largest transcript decline was found in the cardiac muscle
contractile protein myosin, heavy polypeptide 7. Increased beta-
myosin heavy chain gene expression is associated with the develop-
ment of cardiac hypertrophy and mutations in this gene have been
Table 6
Top 25 transcripts that were signiﬁcantly down-regulated with HF (pb0.05). Down-regulated transcripts ranked by fold change.
Identiﬁer Gene title p Fold change
FDR F/NF Function Chrom.
AI535411 Myosin, heavy polypeptide 7, cardiac muscle, beta 0.0023 0.0125 0.18 S 14
AI103845 UDP-N-acetyl-alpha-D-galactosamine: polypeptide
N-acetylgalactosaminyltransferase 13
0.0035 0.0136 0.27 PM 2
AF385402 potassium channel, subfamily K, member 2 0.0068 0.0167 0.33 T 1
AA943734 mitochondrial protein, 18 kDa 0.0013 0.0117 0.34 S 11
M74449 potassium voltage-gated channel, shaker-related subfamily, member 2 0.0002 0.0092 0.34 T
AF134409 RASD family, member 2 0.0017 0.0122 0.35 CS/TT 8
NM_031730 potassium voltage gated channel, Shal-related family, member 2 0.0038 0.0136 0.37 T 6
BE098261 solute carrier family 25 (mitochondrial oxodicarboxylate carrier), member 21 0.0013 0.0116 0.37 T 12
J02997 dipeptidylpeptidase 4 0.0002 0.0087 0.42 D 2
BG378827 putative chloride channel 0.0144 0.0256 0.43 T 7
BI295768 LRP16 protein 0.0110 0.0200 0.46 TT 19
NM_022604 endothelial cell-speciﬁc molecule 1 0.0005 0.0093 0.46 G 13
AW525609 inositol (myo)-1(or 4)-monophosphatase 2 0.0034 0.0135 0.47 O 18
NM_019174 carbonic anhydrase 4 0.0022 0.0124 0.47 B 11
AI170387 chemokine (C-X-C motif) ligand 9 0.0032 0.0133 0.48 CD 5
BF555973 triadin 0.0275 0.0415 0.49 S 10
BE098261 solute carrier family 25 (mitochondrial oxodicarboxylate carrier) member 11 0.0139 0.0251 0.50 T 11
NM_033352 ATP-binding cassette, sub-family D(ALD), member 2 0.0086 0.0186 0.51 T/EM 15
NM_017239 myosin heavy chain, polypeptide 6, cardiac muscle, alpha 0.0131 0.0243 0.52 S 14
AA799574 L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain 0.0061 0.0160 0.52 EM 3
X95189 acyl-Coenzyme A oxidase 2, branched chain 0.0048 0.0143 0.52 EM 14
BF420810 histidine rich calcium binding protein 0.0087 0.0189 0.52 CA 7
AI411446 pyruvate dehydrogenase phosphatase isoenzyme 2 0.0018 0.0122 0.53 EM 8
NM_012506 ATPase Na+/K+ transporting, alpha 3 polypeptide 0.0139 0.0251 0.53 T/EM 7
NM_080399 DNA-damage-inducible transcript 4 0.0218 0.0349 0.53 TT/D 10
89W.W. Brooks et al. / Genomics 95 (2010) 84–92found responsible for genetic dilated cardiomyopathy and HF in
humans [35]. Down-regulation of myosin, heavy chain polypeptide
genes has been noted in the LV from canine tachycardia-induced HF
[12] and rats with HF following myocardial infarction [36]. The
functional consequences of speciﬁc contractile protein changes in
different models of HF, however, remains to be determined.
Studies have suggested that oxidative stress is enhanced in HF
[37]. Free radical formation can affect transcripts regulating ion
channels, Ca2+ homeostasis, mitochondrial function, transcription
factors, DNA binding activity, growth, and apoptosis [38], and has
been shown to induce myocyte hypertrophy, apoptosis, and intersti-
tial ﬁbrosis [37]. In the present study, oxidative stress genes were up-Table 7
Curated summary of pathway changes with HF.
Gene set name Size ES NES NOM
UP with HF
Insulin signaling 17 0.700 1.899 0.000
LVAD_heart failure 63 0.595 1.862 0.000
TGF-β signaling pathway 41 0.630 1.832 0.000
IFN beta signaling 38 0.462 1.843 0.000
Oxidation (Passerini) 17 0.629 1.785 0.000
Complement and coagulation cascades 59 0.589 1.850 0.002
HDAC inhibition 56 0.448 1.661 0.002
Wnt targets 19 0.675 1.843 0.002
Adhesion (Passerini) 36 0.619 1.665 0.002
INOS 72 0.424 1.850 0.004
Apoptosis (Passerini) 36 0.408 1.527 0.006
Inﬂammation (Passerini) 25 0.588 1.743 0.008
Down with HF
Myc signaling (Coller) 15 0.700 1.810 0.000
Alanine and aspartate metabolism 20 0.520 1.550 0.002
Glycerophospholipid metabolism 53 0.350 1.440 0.006
GSEA on SHR with HF vs. SHR without HF gene sets, enriched known pathways and
gene signatures in systolic HF (NOM p-valueb1%). Size, size of gene set; ES, enrichment
score; NES, normalized enrichment score; NOM p-value, nominal p-value. Analysis as
previously described (Subramanian et al. [21]). Recently updated gene sets (MSigDB,
version 2.5) were utilized for GSEA analysis. The array data from total six replicated
samples in failure condition was computed against samples in control group based on
GSEA algorithm.regulated while PPAR gamma (Pparg), a regulator of myocardial
superoxide content and redox homeostasis [39], was downregulated.
The expression level of aldehyde dehydrogenase, a source of cytosolic
reactive oxygen species [40] from the LV, was negatively correlated
with active force of individual papillary muscles from the same heart
(R=−08877, pb0.001). Findings appear consistent with a role for
oxidative stress in the failing SHR heart.
Our ﬁndings from gene set enrichment analyses provide additional
insight into the expression proﬁles associated with systolic HF
progression, such as the enrichment of gene sets involved in TGF-β
and insulin signaling pathways. Upregulation of TGF-β signaling was
identiﬁed by the outcome of GSEA pathway and GO-based analysis.
Increased TGF-β1 mRNA has been found in the LV from aging SHR
during the transition to HF [24,29]. TGF-β and insulin-like growth
factor transcripts have been reported to be upregulated in cardiacTable 8
Curated summary of transcriptomic changes with HF.
Gene set name Size ES NES NOM
UP with HF
Glycosaminoglycan binding 25 0.681 1.874 0.000
Carbohydrate binding 50 0.525 1.847 0.000
TGF-β signaling pathway 31 0.596 1.772 0.000
Nitrogen compound metabolic process 131 0.308 1.389 0.000
Endoplasmic reticulum 241 0.293 1.526 0.002
Proteolysis 154 0.361 1.663 0.006
Phagocytosis 15 0.641 1.654 0.006
Regulation of cell signaling 175 0.396 1.521 0.006
Cation binding 172 0.312 1.510 0.007
Down with HF
Organellar ribosome 19 0.796 1.577 0.002
Mitochodrial ribosome 19 0.796 1.577 0.002
Cofactor biosynthetic process 19 0.667 1.635 0.004
GSEA on SHR with HF vs. SHR without HF gene sets overrepresented GO classes of
biological processes in systolic HF (NOM p-valueb1%). Size, size of gene set; ES,
enrichment score; NES, normalized enrichment score; NOM p-value, nominal p-value.
Analysis as previously described (Subramanian et al. [21]). Recently updated gene sets
(MSigDB, version 2.5) were utilized for GSEA analysis. The array data from total six
replicated samples in failure condition was computed against samples in control group
based on GSEA algorithm.
Table 9
Real-time RT-PCR and differential expression results from microarray experiments.
Gene RT-PCR Microarray
Fold change p Value Fold change
Up-regulated
Lbp 4.85 NS 6.11
Ctss 2.65 NS 2.5
Lox 2.85 NS 2.41
Dbh 10.18 N0.05 1.41
Avpi1 1.73 NS 1.60
Crem 1.24 NS 1.49
Pdcd4 1.55 NS 1.49
Down-regulated
Rasd2 0.46 NS 0.35
Hadhsc 0.71 NS 0.51
Acox2 0.49 NS 0.52
Conﬁrmation of the microarray gene expression for ten randomly selected genes by RT-
PCR. Ratio of expression for each gene in SHR-F group to age-matched SHR without HF.
Fold, relative fold changes as assessed by real-time RT-PCR andmicroarray. Fold change
above 1 denotes upregulated, and fold change below 1 denotes downregulated
expression. p-value, indicates pb0.05 of RT-PCR relative to assessment by microarray.
Bold letters highlights genes with result discrepancy between RT-PCR and microarray
values. Lbp, indicates lipopolysaccharide binding protein; Ctss, cathepsin S; Lox, lysyl
oxidase; Dbh, dopamine beta-hydroxylase; Avpi1, arginine vasopressin; Crem, cAMP
response element modulator; Pdcd4, programmed cell death 4; Rasd2, RASD family
member 2; Hadhcs, L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain; and
Acox2, acyl-Coenzyme A oxidase 2, (branched chain).
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analysis identiﬁed enriched gene sets involving inﬂammation,
oxidative stress and cell death (Tables 7 and 8, and supplemental
tables). GSEA analysis also identiﬁed similarities to human HF prior to
ventricular unloading with an LV assist device [41]. This ﬁnding is of
interest considering the increasing recognition of the role of immune
and inﬂammatory systems in the genesis of HF.Fig. 5. (A) Example of regression plot between expression intensity of lipopolysaccha-
ride binding protein (Lbp level determined by gene chip) and active tension of LV
papillary muscle is shown in the top panel. (B) Expression of lysyl oxidase (Lox level
determined by gene chip) and myocardial stiffness of LV papillary muscle is shown in
the bottom panel. These values represent individual LV gene expression and papillary
muscle function data obtained from the same heart.LV remodeling
Histological data from LV and papillary muscles [4] indicate that
ﬁbrosis and hypertrophy are well established in the compensated SHR
and increases furtherwithHF. It is of interest that progressivemyocardial
ﬁbrosis and the transition to HF can be prevented in aging SHR hearts if
treatmentwith the ACE inhibitor captopril is begun at 12 to14months of
age, or prior to the development of failure [4], consistent with the
recognized importantance of the renin–angiotensin–aldosterone sys-
tem in hypertension induced LV remodeling [24,29]. In the present
study, the increase in ECM-related transcripts (e.g. lysyl oxidase (Lox),
thrombospondin (Thbs4), cathepsins (Ctss)) in SHR-F vs. SHR-NF
correspond to a progression of ﬁbrosis and indicates that the ECM
response is continuing to evolve with the development of systolic HF.
Thrombospondin-4 (Thbs4), whichwas found to increase 1.8-fold in 20-
month-old SHR vs.16-month-old animals [20] was increased more than
3 fold in SHR-F vs. SHR-NF. Fibronectin-1, whichwas up-regulated by 1.5
fold between 20- and 16-month-old SHR [20] was 3.65-fold greater in
SHR-F vs. non failing SHR. The composition of the ECM as well as the
extent ofﬁbrosismay alter cardiac function andmyocardial stiffness. The
expression of the collagen cross-linking enzyme lysyl oxidase (Lox) was
positively correlated with myocardial stiffness noted in the present
papillary muscle studies (Fig. 5B). Lysyl oxidase inhibition with BAPN, a
collagen crosss-link inhibitor, has been shown to modify myocardial
stiffness of hypertrophied hearts [42]. Lysyl oxidase is up-regulated in
human HF [28] and was highly expressed in the SHR-F group. Up-
regulated ECM transcripts have previously been reported in the SHR
with diastolic dysfunction [20]; there are differences comparing age-
matched non-failing and failing SHR in the present study, possibly
consistent with the concept of a progression from diastolic dysfunction
reported by Rysa [20] to systolic dysfunction in the present study.
Conclusions
This investigation describes for the ﬁrst time the association
between functional and structural changes and alternations in gene
expression associated with the development of systolic dysfunction in
the aging SHR model of hypertensive HF. Furthermore, the study
demontrates the relationship between systolic dysfunction in the
intact animal and impairment of intrinsic myocardial contractile
properties. The spectrum of changes in gene expression reported in
the SHR with diastolic dysfunction is expanded to include a broad
spectrum of transcript changes involving many processes including
inﬂammation, apoptosis, oxidative stress and altered cell signaling
pathways in addition to a further upregulation of ECM transcripts,
occurring with the development of systolic dysfunction. While some
transcriptional changes associated with systolic HF may be secondary,
GSEA ﬁndings support the concept that these identiﬁed pathways and
mechanisms may play an important role in myocardial dysfunction
and adverse remodeling associated with hypertensive HF.
Materials and methods
Animal model
Sixteen male SHR were purchased from Taconic (Germantown,
NY). All rats were housed two per container and fed regular rat chow
and water with a 12-h light/dark cycle. All animal experiments were
performed in accordance with the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the Animal Studies
Committee at the Boston VA Healthcare System. Animals were
monitored several times per week for the presence of tachypnea
and labored respiration, body weight and blood pressure (indirect tail
cuff method) were determined monthly. Animals underwent echo-
cardiographic study every 4 to 6 weeks or upon demonstration of
respiratory changes. Those animals found to have HF were studied at
91W.W. Brooks et al. / Genomics 95 (2010) 84–92the time of HF, and compared to age-matched SHR without HF. Four
SHR died prior to study.
Echocardiography
Chamber dimensions and LV function were measured using trans-
thoracic echocardiography as previously described [3,4]. Brieﬂy, ratswere
lightly anesthetized with isoﬂurane (1.5% to 2% by O2 inhalation) and
placed in the supineposition. 2DguidedM-mode studieswereperformed
using a 10-MHz linear array transducer and images at the tip of the left
ventricular papillary muscle recorded. The thickness of the posterior and
anterior walls of the LV chamber and the LV chamber diameter during
systole and diastole were measured. All parameters were measured over
at least six consecutive cardiac cycles. Averages were used to calculate LV
ejection fraction, LV fractional shortening, LV end-diastolic and systolic
diameters, and LV systolic and diastolic volumes.
Isolated muscle studies
After echocardiography, the hearts were quickly removed, weighed,
and placed in oxygenated Krebs–Henseleit solution at 28 °C. The LV
posterior papillary muscle was dissected free, mounted between two
spring clips, and placed vertically in a 100-ml acrylic chamber contain-
ing oxygenated Krebs–Henseleit solution, and then attached to a low-
inertia DC pen motor and semiconductor strain gauge force transducer
aspreviously described [4,23]. A digital computerwith ananalog/digital
interface allowed control of either force or length of the preparation.
Force and length data were sampled at a rate of 1.0 kHz and stored on
disk for later analysis. A central segment scanning systemwasutilized to
measure passive stiffness of the central segment of the papillarymuscle
(kcs) as previously described [22,23].
Force–velocity relations (shortening velocity vs. load) were
determined frommuscle shortening velocitymeasurements following
“quick releases” 100ms after stimulation to loads ranging from0.5 g to
peak isometric force. Valueswere subsequently normalized formuscle
length and cross-sectional area, as described previously [22,23].
cDNA microarray
Samples of LV tissue were obtained at the time of study and
immediately frozen in liquid nitrogen. Total RNA was isolated from
approximately 30mg of frozen left ventricle using RNeasymini columns
for ﬁbrous tissue (Qiagen, Valencia, CA). 30 mg of frozen tissue was
pulverized and transferred to a tube containing 300 :l RLT buffer. The
sample was homogenized using a Omni PCR homogenizer (Omni
International). Debris was removed from the lysate using QIA shredder
(Qiagen) following proteinase K digestion at 55 °C for 10 min. Total RNA
was isolated using the RNeasy spin columns following on-columnDNase
treatment to remove any contaminating DNA. The integrity and
concentration of the different RNA samples were determined using
RNA Nano LabChip (Agilent Technologies, Inc., Santa Clara, CA).
Individual samples containing equal amounts of total RNA from each
LV were prepared. Expression values were compared between two
groupsof animals: non-failing SHRandun-treated SHRwithheart failure.
Target preparation, hybridization to the Affymetrix 230 2.0 array, and
detection was performed by the Genomics Department at Boston
University School of Medicine. All hybridizations were performed on
six individual samples for each of two groups (total of 12 independent
hybridizations). The normalized array data and raw data ﬁles are
available from GEO. The GEO serial number is GSE19210.
Microarray quantiﬁcation, normalization and analysis
Transcript-level expression estimates of the probe-level hybrid-
ization intensities were derived using the MAS 5 algorithm in
Affymetrix GeneChip software (version 3.3; Affymetrix, Santa Clara,CA). Only those transcripts that were detected above background in at
least one sample (i.e. at least one sample had an MAS 5 detection call
of “present”) were included in subsequent analyses. Statistically
signiﬁcant differences in mean values were tested by Student's t-test
and corrected for multiple comparisons using the False Discovery Rate
(FDR) method of Benjamini and Hochberg [43]. An FDRb0.05 was
considered evidence of statistically signiﬁcant differential expression
between groups. For each gene, the p value was used to determine
signiﬁcance rather than fold change, in order to maximize the
proportion of candidate gene changes.
To identify the enriched gene sets, pathways or GO term gene
functions, the gene set enrichment analysis method [21] was adopted.
This bioinformatic tool evaluates all signiﬁcantly measured targets
derived from a microarray experiment at the level of gene sets, which
are deﬁned based on prior biological knowledge. GSEA determines
whether genes belonging to a biological pathway or a previously
determined functional group are signiﬁcantly over-represented at the
top or bottom of a ranked gene list compared to controls without a
predeﬁned cut-off value. Thus, biologically relevant information is not
missed by losing target genes due to an “arbitrarily” chosen cut-off
value. The two curated gene sets C2 and C5 (i.e. SHR with HF vs. SHR
without HF) within the up-to-date molecular signature database
(MSigDB-v2.5: http://www.broadinstitute.org/gsea/msigdb/index.jsp)
was used to perform such enrichment analysis for either pathways or
GO term functions, respectively. All parameters in the analysis were set
to default.
Quantitative real-time PCR
To independently conﬁrm the differential expression data obtained
by microarray analysis, real time quantitative reverse transcription
(RT)-PCRwas utilized to determine the relative expression of selected
genes. cDNA for RT-PCR was produced using 1 μg of total RNA in a 20:
l reaction containing ﬁrst strand buffer, dTTP, dATP, dGTP and dCTP
(ﬁnal concentration, 0.4 mM each), 100 U of Superscript II (Life
technologies), 10 U of RNase inhibitor, 500 ng of randomhexamer. The
cDNA synthesis reaction mixture was incubated at 42 °C for 1 h. Then,
real-time PCR was carried out in the presence of speciﬁc primers for
each transcript. RT-PCR was performed in triplicate on 10 ng of each
cDNA with the SYBR Green master mix using the LightCycler PCR
system following the manufacturer's instructions (Roche Diagnostics,
Mannheim, Germany). To insure that there was no genomic
contamination of cDNA and no primer dimer artifact, real-time
reactions containing cDNA generated without reverse transcriptase
and reactions containing primers alone were also included. All PCR
reactions were repeated six times per sample, and expression level
normalized to 18 S expression with the standard curve method. The
resulting averages between groups were then compared statistically.
Pathological and histological analysis of hearts and liver
After removal of the papillary muscles, the right ventricle (RV) and
left ventricle (LV) were carefully separated. Myocardial and liver tissue
samples were gently blotted and weighed. LV and RV wet weight
normalized by body weight (e.g. LV/BW and RV/BW) and LV by tibia
length (LV/TL) were used as indices of ventricular hypertrophy. Water
content of tissue samples was determined as previously described [22].
Samples of LV free wall were placed in 10% formalin ﬁxative, and
prepared for microscopy and histological analysis as previously
described [4,23,24]. At the conclusion of the mechanical studies, the
central segment of the LV papillary muscle was ﬁxed with a preload
equivalent to the resting stress at Lmax. Histological sections of the
central segment of LV papillary muscles were stained with Masson's
trichrome. Areas of connective tissue network and myocytes were
quantiﬁed by a semiautomated computer-based video analysis
system with an Image-Pro Plus software package (Silver Spring, MD).
92 W.W. Brooks et al. / Genomics 95 (2010) 84–92Statistical analysis
Data are expressed as mean±SD unless otherwise stated. Data set
comparisons were performed with Student's unpaired, two-tailed t-
test. Differences in mean values were considered statistically
signiﬁcant at a probability level of less than 5% (pb0.05).
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